Gastrointestinal stromal tumors of the pancreas.

Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature. World J Surg Oncol (2014) 1.03

Primary extragastrointestinal stromal tumor arising in the pancreas: report of a case. Surg Today (2012) 0.98

Pancreatic extragastrointestinal stromal tumor: A case report and comprehensive literature review. World J Gastrointest Surg (2014) 0.91

Pancreatic extra-gastrointestinal stromal tumour masquerading as a bleeding duodenal mass. BMJ Case Rep (2012) 0.78

Pancreatic extra-gastrointestinal stromal tumour with documentation of C-kit mutation: a case report. J Clin Diagn Res (2015) 0.77

Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases. Case Rep Oncol Med (2016) 0.76

GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases. Am J Surg Pathol (2017) 0.75

Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report. Oncol Lett (2016) 0.75

Extragastrointestinal stromal tumor arising in the pancreas: a case report with a review of the literature. JOP (2010) 1.85

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39

Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57

Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44

Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43

Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38

Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer (2010) 1.35

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30

Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17

Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07

Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06

Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 1.06

First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 1.05

Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04

Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03

Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02

Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02

Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00

Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99

Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96

IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96

Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95

Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.94

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP (2008) 0.94

Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res (2010) 0.93

Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93

Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93

FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol (2013) 0.90

Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90

Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89

Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89

Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89

Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res (2010) 0.88

Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.88

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP (2013) 0.87

Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87

Early detection of pancreatic cancer. JOP (2012) 0.87

Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87

Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87

Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87

Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.86

Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86

Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86

Quality of life in patients with pancreatic cancer. JOP (2012) 0.86

Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.86

Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.86

Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85

Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85

Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85

Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85

Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.85

Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84

Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84

Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.84

Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.84

Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84

Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.84

Advancements in the management of pancreatic cancer. JOP (2009) 0.83

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83

Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83

Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83

PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83

Diabetes and pancreatic cancer. JOP (2014) 0.83

Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.83

First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83

Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82

Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82

Biomarkers in neuroendocrine tumors. JOP (2013) 0.82

The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82

Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82

Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82

Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81

Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81

Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP (2008) 0.81

Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81

Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81

Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP (2013) 0.81